Meanings of onchocerciasis in anglès

Mass treatment with IVM is an integral component of the onchocerciasis control programmes.

Bovine nodular onchocercomata represent an interesting model for human onchocerciasis.

As response to an endemic disease, programs have focused on the control of onchocerciasis transmission.

First, mild-to-moderate chronic inflammatory cellular infiltration was present in the conjunctiva of the onchocerciasis patients.

River blindness or onchocerciasis is an eye and skin disease caused by the filaria worm.

Nodding syndrome (NS) is an epileptic disorder occurring in children in African onchocerciasis endemic regions.

The vaccines developed in this study have the potential of reducing the morbidity associated with onchocerciasis in humans.

This paper reviews the contributions that such concentrated efforts to control and eliminate onchocerciasis make to achieving select MDGs.

Lymphatic filariasis and onchocerciasis are diseases of severe morbidity that affect the poorest of the poor in the world.

Historically, onchocerciasis control targeted vector breeding sites, but the current strategy relies on mass administration of a single drug, ivermectin.

Here, we argue that prophylactic and therapeutic vaccines would accelerate elimination efforts and safeguard the enormous strides made in onchocerciasis control.

This immunomic approach not only demonstrates the power of this postgenomic discovery platform but also provides additional tools for onchocerciasis control programs.

The results support the validity of the assumption that a unique status of immunity develops in certain individuals living in areas where onchocerciasis is endemic.

That altruism has hugely helped to combat onchocerciasis -aka river blindness -lymphatic filariasis and other parasitic diseases in Africa, Latin America and Yemen.

Accurate detection of filarial parasites in humans is essential for the implementation and evaluation of mass drug administration programs to control onchocerciasis and lymphatic filariasis.

Antibodies to the OV9M protein are present in 40-60% of both patently infected and non-patent individuals residing in onchocerciasis endemic areas.